EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update
Annals of the Rheumatic Diseases · 2025-06 · 84 (6) · 910-926
DOI: 10.1016/j.ard.2025.02.023 ↗Kurz gefasst
Leitlinie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-06. Verfasst von Linda Rüegg und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland. Hauptthemen laut MEDLINE: Antirheumatic Agents, Lactation, Pregnancy Complications, Reproduction. Die Arbeit wurde bisher 183-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EULAR.
Themen: Stillen
Abstract (Originalsprache)
OBJECTIVES: To update the existing European Alliance of Associations for Rheumatology (EULAR) points to consider (PtC) for use of antirheumatic drugs in reproduction, pregnancy, and lactation, including additional drugs and adverse outcomes as well as paternal drug safety. METHODS: According to the EULAR standardised operating procedures, an international task force (TF) defined the questions for a systematic literature review, followed by formulation of the updated statements. A predefined voting process was applied to each overarching principle and statement. Level of evidence and strength of recommendation were assigned, and participants finally provided their level of agreement for each item. RESULTS: The TF proposes 5 overarching principles and 12 recommendations for the use of antirheumatic drugs before and during pregnancy, through lactation, and in male patients. The current evidence indicates that synthetic disease-modifying antirheumatic drugs (DMARDs) compatible with pregnancy include antimalarials, azathioprine, colchicine, cyclosporine, sulfasalazine, and tacrolimus. Regarding nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, a more restrictive approach to their use during pregnancy is recommended. Based on an individualised risk-benefit assessment, all tumour necrosis factor inhibitor (TNFi) biologic DMARDs (bDMARDs) can be used throughout pregnancy, and non-TNFi bDMARDs may be used if needed. In relation to lactation, compatible drugs include antimalarials, azathioprine, colchicine, cyclosporine, glucocorticoids, intravenous immunoglobulin (IVIG), NSAIDs, sulfasalazine, and tacrolimus. All bDMARDs are considered compatible with breastfeeding. Concerning the use of drugs in men, compatible options include antimalarials, azathioprine, colchicine, cyclosporine, IVIG, leflunomide, methotrexate, mycophenolate, NSAIDs, glucocorticoids, sildenafil, sulfasalazine, tacrolimus, and bDMARDs. CONCLUSIONS: The updated recommendations provide consensus guidance and will help to improve the quality of care of patients during the phases of reproduction, pregnancy, and lactation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
- Department of Rheumatology, Vall d'Hebron University Hospital, Barcelona, Spain.
- Department of Rheumatology, Pontoise Hospital, Pontoise, France.
- University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERNReconnect and RITA-ERN Member) with Nephrology and Dialysis Unit, Turin, Italy; Center of ImmunoRheumatology and Rare Diseases…
- Department of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Förderung
- EULAR
Zitieren
APA
Rüegg, L., Pluma, A., Hamroun, S., Cecchi, I., Perez-Garcia, L. F., Anderson, P. O., Andreoli, L., Wirström, S. B., Boyadhzieva, V., Chambers, C., Costedoat-Chalumeau, N., Dolhain, R. J. E. M., Fischer-Betz, R., Giles, I., Gøtestam-Skorpen, C., Hoeltzenbein, M., Marchiori, F., Mayer-Pickel, K., Molto, A., …, & Förger, F. (2025). EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the Rheumatic Diseases, 84(6), 910-926. https://doi.org/10.1016/j.ard.2025.02.023
Vancouver
Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the Rheumatic Diseases. 2025;84(6):910-926. doi:10.1016/j.ard.2025.02.023
BibTeX
@article{Regg2025,
author = {Rüegg, Linda and Pluma, Andrea and Hamroun, Sabrina and Cecchi, Irene and Perez-Garcia, Luis Fernando and Anderson, Philip O and Andreoli, Laura and Wirström, Sara Badreh and Boyadhzieva, Vladimira and Chambers, Christina and Costedoat-Chalumeau, Nathalie and Dolhain, Radboud J E M and Fischer-Betz, Rebecca and Giles, Ian and Gøtestam-Skorpen, Carina and Hoeltzenbein, Maria and Marchiori, Francesca and Mayer-Pickel, Karoline and Molto, Anna and Nelson-Piercy, Catherine and Nielsen, Ole Haagen and Tincani, Angela and Wallenius, Marianne and Zbinden, Astrid and Meissner, Yvette and Finckh, Axel and Förger, Frauke},
title = {EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
number = {6},
pages = {910--926},
doi = {10.1016/j.ard.2025.02.023}
}
EUVIMED